. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013 Mar;12(3):233-43. Epub 2013 Jan 31 PubMed.

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Research Brief: Octapharma IVIg Iffy in Phase 2 Trial
  2. Quick-and-Early IVIG Therapy: Hints of Promise

Therapeutics

  1. Octagam®